Tyrosine Kinase Inhibitors: all 10,469 studies that test it
Page 62 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.
- Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory OsteosarcomaSuspendedNCT04824352Phase 2
- Keynatinib in Treated Patients with NSCLC and Brain MetastasesCompletedNCT04824079Phase 2
- A Study of Anlotinib in the Treatment of Recurrent High-grade GliomaStatus unknownNCT04822805Phase 2
- Evaluation of Effect and Tolerance of the Association of Baricitinib and Phototherapy Versus Phototherapy in Adults With Progressive VitiligoCompletedNCT04822584Phase 2
- A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04819100Phase 3
- Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)TerminatedNCT04816604Phase 2
- Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic CancerStatus unknownNCT04814485Phase 2
- A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous CarcinomaCompletedNCT04814108Phase 2
- To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 FusionStatus unknownNCT04814056Phase 4
- Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT04813406Not applicable
- Best EGFR-TKI Sequence in NSCLC Harboring EGFR MutationsStatus unknownNCT04811001Phase 2
- A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary CancerStatus unknownNCT04809142Phase 3
- Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain MetastasesActive, not recruitingNCT04808752Phase 2
- Clinical Trial to Evaluate UV-light-induced Allergic Skin Reactions After Application of Delgocitinib CreamCompletedNCT04807751Phase 1
- Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian CancerActive, not recruitingNCT04807166Phase 2
- A Pharmacokinetic Study of TQB3101 in Chinese Healthy SubjectsCompletedNCT04804904Phase 1
- Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell CancersTerminatedNCT04804254Phase 1
- SARC038: Phase 2 Study of Regorafenib and Nivolumab in OsteosarcomaActive, not recruitingNCT04803877Phase 2
- Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic CancerStatus unknownNCT04803851Phase 1/2
- Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell LymphomaActive, not recruitingNCT04802590Phase 2
- A Study to Explore the Effect of Food Before a Single Dose of SitravatinibCompletedNCT04800614Phase 1
- Tofacitinib as a GC Sparing Agent for Polymyalgia RheumaticaCompletedNCT04799262Phase 2
- A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy VolunteersCompletedNCT04798638Phase 1
- Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLCStatus unknownNCT04797806Phase 3
- SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell CancerStatus unknownNCT04797507Phase 2
- Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase InhibitorsCompletedNCT04795427Phase 2
- Intravenous Imatinib in Mechanically Ventilated COVID-19 PatientsTerminatedNCT04794088Phase 2
- Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon MutationsCompletedNCT04790409Phase 2
- Tucatinib Together With Pembrolizumab and TrastuzumabTerminatedNCT04789096Phase 2
- PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse SequenceCompletedNCT04787341Phase 2
- A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)Status unknownNCT04787328Phase 2
- Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFRStatus unknownNCT04785742Phase 2
- ALSENLITE: Senolytics for Alzheimer's DiseaseActive, not recruitingNCT04785300Phase 1/2
- A Study of HA121-28 Tablets in Advanced Biliary Tract CancerTerminatedNCT04784520Phase 2
- Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue SarcomaActive, not recruitingNCT04784247Phase 2
- Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter TransformationWithdrawnNCT04781855Phase 1
- Neratinib in Patients With Metastatic Castration-Resistant Prostate CancerWithdrawnNCT04781374Phase 2
- The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract CancersActive, not recruitingNCT04781192Phase 1/2
- A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)Status unknownNCT04778800Not applicable
- Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal CancerStatus unknownNCT04777162Phase 2
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS TumorsActive, not recruitingNCT04774718Phase 1/2
- Baricitinib in New-onset Type 1 DiabetesCompletedNCT04774224Phase 2
- A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA SignalingCompletedNCT04773782Phase 1/2
- A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of SitravatinibCompletedNCT04772612Phase 1
- Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy ParticipantsCompletedNCT04771390Phase 1
- Advanced Lung Tumor Treated by Osimertinib Plus AnlotinibCompletedNCT04770688Phase 1/2
- Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant MetastasisStatus unknownNCT04769908Phase 2
- A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of AsthmaCompletedNCT04769869Phase 1
- Study to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib CapsuleCompletedNCT04768985Phase 1
- The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid TumorsStatus unknownNCT04768868Phase 1
- Tofacitinib for the Treatment of Refractory Immune-related Colitis from Checkpoint Inhibitor Therapy- TRICK StudyTerminatedNCT04768504Phase 2
- Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 InhibitorsCompletedNCT04767906Phase 2
- Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue SarcomaStatus unknownNCT04765228Phase 2
- Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT04765111Phase 2
- SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIsCompletedNCT04764214Phase 2
- Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid TumorsStatus unknownNCT04764084Phase 1
- Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II StudyStatus unknownNCT04764006Phase 2
- A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).WithdrawnNCT04760288Phase 3
- Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid CancerActive, not recruitingNCT04759911Phase 2
- A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric CancerActive, not recruitingNCT04757363Phase 2
- Surufatinib Renal Impairment StudyCompletedNCT04755088Phase 1
- Surufatinib Hepatic Impairment StudyCompletedNCT04755075Phase 1
- Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate CancerTerminatedNCT04754425Phase 2
- Efficacy and Safety of Tofacitinib in Patients With COVID-19 PneumoniaCompletedNCT04750317Phase 2
- First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)CompletedNCT04747197Phase 1
- First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid TumorsTerminatedNCT04746612Phase 1
- An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric CancerActive, not recruitingNCT04745988Phase 2
- iPSC-based Drug Repurposing for ALS Medicine (iDReAM) StudyCompletedNCT04744532Phase 1/2
- Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm TrialStatus unknownNCT04743687Phase 2
- Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04743505Phase 1/2
- Drug-drug Interaction Study of CTP-543 and Itraconazole in Healthy Adult SubjectsCompletedNCT04743414Phase 1
- A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study of BS HH 002.SA in Patients With AML and MDSStatus unknownNCT04743115Phase 1
- Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid TumorsCompletedNCT04742959Phase 1/2
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaActive, not recruitingNCT04739813Phase 1
- CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLCTerminatedNCT04739358Phase 1/2
- Drug-drug Interaction Study With GLPG3667 and Midazolam in Healthy SubjectsCompletedNCT04736927Phase 1
- A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)Active, not recruitingNCT04734262Phase 2
- Second-line Surufatinib Combined With Chemotherapy in Advanced CRCStatus unknownNCT04734249Phase 2
- Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal CancerStatus unknownNCT04733963Phase 2
- An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood CancerActive, not recruitingNCT04733534Phase 2
- Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung CancerStatus unknownNCT04731909Not applicable
- Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid CancerWithdrawnNCT04731740Phase 2
- Combination Therapy for First Line Treatment of Advanced Cervical CancerStatus unknownNCT04731038Phase 1
- Pembrolizumab And Lenvatinib In Leptomeningeal MetastasesTerminatedNCT04729348Phase 2
- Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract CancerActive, not recruitingNCT04727996Phase 2
- Anlotinib Combined With STUPP for MGMT Nonmethylated GlioblastomaStatus unknownNCT04725214Phase 2
- Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular CarcinomaStatus unknownNCT04724226Phase 2
- Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALLActive, not recruitingNCT04722848Phase 3
- A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLLActive, not recruitingNCT04722172Phase 2
- Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.CompletedNCT04720131Phase 2
- Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCCStatus unknownNCT04718909Phase 2
- Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic CancerStatus unknownNCT04718701Phase 2
- Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast CancerStatus unknownNCT04717531Phase 2
- PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal CancerStatus unknownNCT04715633Phase 2
- Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell CarcinomaStatus unknownNCT04714697Phase 2
- Study on the Bioavailability of SHR0302 in Healthy SubjectsCompletedNCT04712838Phase 1
- A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple SclerosisActive, not recruitingNCT04711148Phase 2
- Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIentsCompletedNCT04710628Phase 2
- Relative Bioavailability Study and Food Effect Study of TT-00420 (Tinengotinib) Capsule and Tablet Formulations in Healthy VolunteersCompletedNCT04705922Phase 1
- Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCLStatus unknownNCT04705129Phase 2